Oncology

28 years of oncology expertise transforming promising ideas into breakthrough therapies

In-vitro cytotoxicity testing and functional biology biomarker panels for anti-cancer drug development.

2D Cancer Cells and Primary Cell Lines (2)-1

Oncology Biomarker Panels Designed for Early Drug Development

Apoptosis and Epithelial Tumors

Biomarker	Cancer	Role
Cleaved Cytokeratin 18 (M30)	Breast, colon, liver	Apoptotic epithelial cell marker
Cytokeratin 18 (total)	Breast, colon, liver	Total epithelial cell death
Caspase 3/7 Activity	Broad solid tumors	Apoptotic pathway activation
High Mobility Group Box 1 (HMGB1)	Various solid tumors	Marker of tumor cell death/necrosis
Galectin-3	Thyroid, breast, colorectal	Tumor progression and immune evasion

Angiogenesis and Tumor Growth

Biomarker	Cancer	Notes
VEGF-A	Breast, colon, renal, lung	Key angiogenesis driver
VEGF-C	Breast, colorectal	Lymphangiogenesis
VEGF-D	Various solid tumors	Lymphatic metastasis potential
VEGFR1	Solid tumors	VEGF receptor; targetable
PDGF-AA/AB/BB	Glioblastoma, sarcoma, pancreatic	Tumor growth and stromal activation
FGF-basic	Breast, colon, melanoma	Angiogenesis
PIGF	Solid tumors	Tumor vascular remodeling
Tie-2	Tumor vasculature	Endothelial activation marker

Immuno-Oncology and Tumor Microenvironment

Biomarker	Cancer	Notes
4-1BB (CD137)	Solid tumors, immunotherapy	T-cell co-stimulation, checkpoint target
Granzyme B	Broad solid tumors	Cytotoxic T-cell activity
Perforin	Solid tumors	T/NK cell-mediated tumor killing
Galectin-1	Glioblastoma, pancreatic	Tumor immune evasion
TNF-α	Various	Inflammatory marker, tumor progression
IL-6	Lymphoma, breast, prostate	Chronic inflammation, tumor-promoting
IL-8	Melanoma, ovarian, lung	Angiogenesis, metastasis
MCP-1 (CCL2)	Breast, prostate, ovarian	Tumor-associated macrophage recruitment
MIP-1β (CCL4)	Tumor microenvironment	Immune cell recruitment
TARC (CCL17)	Hodgkin lymphoma	Immune microenvironment

Inflammation and Tumor Progression

Biomarker	Cancer	Notes
CRP	Various cancers	General inflammation
SAA	Breast, lung	Acute phase protein elevated in tumor progression
ICAM-1 / VCAM-1	Metastatic tumors	Endothelial activation, metastasis potential
TGF-β1	Breast, colon, pancreatic	Tumor progression, immune modulation
TGF-α	EGFR-driven tumors	Tumor proliferation
Galectin-1	Solid tumors	Immune evasion

Hematologic and Multiple Myeloma

Biomarker	Cancer	Notes
Beta-2-Microglobulin	Multiple myeloma, lymphoma	Disease progression marker
Fms-Related Tyrosine Kinase 3 Ligand (Flt3L)	Leukemia	Hematopoietic growth, prognosis
IL-1β, IL-10, IL-12p70	Leukemia, lymphoma	Immune modulation
TNF-β	Lymphoma	Immune/inflammatory context

Biomarkers Organized by Cancer Type

While our functional biology–based oncology panels group biomarkers by pathway and mechanism of action, many programs are organized around specific tumor indications. To support indication-driven development strategies, we also provide a comprehensive listing of our oncology biomarkers organized by cancer type, making it easy to align panel selection with your therapeutic focus.

Download PDF

TEST FASTER. COMPARE EASIER. DISCOVER MORE. Compare, Combine and Validate Against 50+ Proven Cancer Drugs

Access a curated panel of approved and investigational oncology drugs for immediate comparison and combination studies, alongside testing across 380 human cancer cell lines.

Cancer Drugs Available for Research Purposes

Adrucil - Fluorouracil (5FU)
Artesunate
Artemisinin
Avastin
Bortezomib (Valcade)
Camptothecin
Carboplatin
Cyclophosphamide (Cytoxan)
Cisplatin, Cisplatinum Orcis- Diamminedichloroplatinum (II) (data)
Dasatinib

Doxorubicin (data)
Erlotinib (data)
Etoposide
Gefitinib (Iressa)
Gemcitabine Hydrochloride
Imatinib (Gleevec)
Irinotecan HCl
Ifosfamide
Leptomycin B
Mitomycin C (data)

Neomycin Sulfate
a-Solanine
Paclitaxel (Taxol)
Sorafenib
Staurosporine
Tamoxifen
Tomatine
Vinblastine
Vincristine

Peptide Therapeutics Development

Lead Drug Optimization Services

Antibody-Drug Conjugates (ADCs) Analytical Characterization Drug-to-antibody ratio (DAR) by HIC-HPLC Functional Potency Cell-killing mechanisms Proliferation inhibition (MTTXTT), apoptosis (caspas (1)

Cyclization

Biotinylation

Phosphorylation

Glycosylation

Binding of Specific Small MW Toxic-Drug

Non-Radioactive Cytotoxicity Assays

Multi-Tox Glo Multiplex Assay & ApoGlow

From Discovery to IND: Oncology Solutions

ChatGPT Image Feb 6, 2026, 03_55_50 PM-1

Biomarkers

Bioassays

ChatGPT Image Feb 6, 2026, 03_55_50 PM-3-1

Cytokines

mAbs

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-06-47-8201-PM

Bioanalysis

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-07-33-6836-PM

Cell & Gene Therapy

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-08-15-7797-PM

Small Molecule

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-08-50-3909-PM

Antibody Development

Biosimilars

ChatGPT Image Feb 6, 2026, 03_55_50 PM-Feb-06-2026-09-10-14-1794-PM

Molecular Diagnostics

High Impact Anti-Cancer Drug Screening

SBH Sciences is actively collaborating with Karyopharm Therapeutics on its anti-cancer development program. We have used over 200 cancer cell lines in this collaboration and are continuing to screen for promising anti-cancer drugs. SBH Sciences and Karyopharm Therapeutics have presented 10 scientific abstracts together.

View Abstracts